Loading...
01/10 16:01
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings report shows mixed results: strong growth in Fanapt sales but declines in PONVORY and HETLIOZ, coupled with a significant net loss increase due to higher expenses. The Q&A revealed uncertainties about PONVORY's revenue dispute and unclear management responses. Despite some positive guidance on Bysanti and potential future products, the overall sentiment is negative due to financial losses and market uncertainties, likely leading to a stock price decline in the next two weeks.
Fanapt revenue Increased by 27% compared to the same period in the prior year, driven by the launch of the bipolar I indication.
Total revenue from 3 commercial branded products (Fanapt, HETLIOZ, PONVORY) Reached $102.6 million in the first 6 months of 2025, a 5% increase compared to $97.9 million for the same period in 2024. The increase was primarily due to growth in Fanapt revenue as a result of the bipolar commercial launch.
Fanapt net product sales $52.8 million for the first 6 months of 2025, a 21% increase compared to $43.7 million in the same period in 2024. This increase was attributable to an increase in volume.
HETLIOZ net product sales $37.1 million for the first 6 months of 2025, a 4% decrease compared to $38.8 million in the same period in 2024. The decrease was due to a decrease in volume, partially offset by an increase in price net of deductions.
PONVORY net product sales $12.7 million for the first 6 months of 2025, an 18% decrease compared to $15.4 million in the same period of 2024. The decrease was due to a decrease in volume and a decrease in price net of deductions.
Net loss $56.7 million for the first 6 months of 2025 compared to a net loss of $8.7 million for the same period in 2024. The increase in net loss was driven by higher SG&A expenses related to commercial launches and higher R&D expenses.
Operating expenses $182.2 million for the first 6 months of 2025 compared to $117.3 million for the same period in 2024. The $64.8 million increase was primarily driven by higher SG&A expenses and R&D expenses.
Cash, cash equivalents, and marketable securities $325.6 million as of June 30, 2025, representing a decrease of $49.1 million compared to December 31, 2024, and a decrease of $15.4 million compared to March 31, 2025.
Total revenues for Q2 2025 $52.6 million, a 4% increase compared to $50.5 million for Q2 2024. The increase was primarily due to growth in Fanapt revenue as a result of the bipolar commercial launch.
Fanapt net product sales for Q2 2025 $29.3 million, a 27% increase compared to $23.2 million in Q2 2024 and a 24% increase compared to $23.5 million in Q1 2025. The increase was primarily attributable to an increase in volume.
HETLIOZ net product sales for Q2 2025 $16.2 million, a 13% decrease compared to $18.7 million in Q2 2024. The decrease was primarily attributable to a decrease in volume and price net of deductions.
PONVORY net product sales for Q2 2025 $7.1 million, a decrease of 18% compared to $8.6 million in Q2 2024 and an increase of 26% compared to $5.6 million in Q1 2025. The decrease compared to Q2 2024 was due to a decrease in price net of deductions, partially offset by higher volume.
Net loss for Q2 2025 $27.2 million compared to a net loss of $4.5 million for Q2 2024. The increase in net loss was driven by higher SG&A expenses and R&D expenses.
Operating expenses for Q2 2025 $91.1 million compared to $60.6 million in Q2 2024. The $30.5 million increase was primarily driven by higher SG&A expenses and R&D expenses.
Fanapt: Revenue increased by 27% compared to the same period in the prior year, driven by the launch of the bipolar I indication. Fanapt is now promoted in the U.S. across all 50 states with a dedicated sales force of approximately 300 representatives. Total prescriptions and new-to-brand prescriptions reached new highs in the second quarter.
HETLIOZ: Continues to be the market share leader despite the availability of generic products. However, net product sales decreased by 4% in the first 6 months of 2025 compared to the same period in 2024.
PONVORY: Net product sales decreased by 18% in the first 6 months of 2025 compared to the same period in 2024. However, new patient prescriptions in the second quarter of 2025 grew to a record high since the commercial launch.
Bysanti: The NDA for Bysanti for the acute treatment of bipolar I disorder and schizophrenia was accepted by the FDA with a PDUFA target action date of February 21, 2026. Exclusivity could extend into the 2040s.
Fanapt Expansion: Fanapt is now promoted across all 50 U.S. states with a sales force of 300 representatives. Face-to-face calls increased by over 40% compared to Q1 2025 and by over 400% compared to Q2 2024.
PONVORY Expansion: A specialty sales force is being grown to approximately 50 representatives by Q3 2025 to market PONVORY to neurology prescribers.
Revenue Growth: Total revenue for the first 6 months of 2025 was $102.6 million, a 5% increase compared to the same period in 2024. Fanapt revenue growth was the primary driver.
Operating Expenses: Operating expenses for the first 6 months of 2025 were $182.2 million, a $64.8 million increase compared to the same period in 2024, driven by higher SG&A and R&D expenses.
Pipeline Development: Vanda is advancing multiple clinical programs, including Bysanti for bipolar I disorder and schizophrenia, tradipitant for motion sickness, and imsidolimab for generalized pustular psoriasis. The company aims to have 6 products commercially available by 2026.
Regulatory Advocacy: Vanda submitted a public response to the HHS proposing changes to FDA regulations to streamline the drug approval process.
HETLIOZ revenue decline: HETLIOZ net product sales decreased by 4% in the first 6 months of 2025 compared to the same period in 2024, and by 13% in Q2 2025 compared to Q2 2024. This decline is attributed to reduced volume and increased generic competition, which could lead to further significant revenue declines in future periods.
PONVORY revenue decline: PONVORY net product sales decreased by 18% in the first 6 months of 2025 compared to the same period in 2024, primarily due to reduced volume and price net of deductions. This trend poses a challenge to sustaining revenue growth.
Increased operating expenses: Operating expenses rose by $64.8 million in the first 6 months of 2025 compared to the same period in 2024, driven by higher SG&A and R&D expenses related to commercial launches and licensing agreements. This increase has contributed to a net loss of $56.7 million in the first half of 2025.
Net loss: The company reported a net loss of $56.7 million for the first 6 months of 2025, a significant increase from the $8.7 million net loss in the same period in 2024. This is attributed to higher operating expenses and challenges in revenue growth.
HETLIOZ inventory variability: HETLIOZ net product sales are impacted by changes in inventory stocking at specialty pharmacy customers, leading to potential variability and uncertainty in future revenue.
Fanapt commercialization costs: The expansion of the Fanapt sales force and marketing efforts for its bipolar I disorder indication have significantly increased SG&A expenses. While these investments aim to drive future revenue, they currently contribute to financial strain.
Regulatory risks: The approval of new drugs such as Bysanti and tradipitant is subject to FDA review, with potential delays or rejections posing risks to future revenue streams.
Cash depletion: Cash reserves decreased by $49.1 million in the first half of 2025, driven by net losses and increased investments in commercial and R&D activities. This trend could impact the company's financial flexibility.
Fanapt Revenue Growth: Fanapt revenue is expected to grow on a quarterly basis with an accelerating trajectory as the year progresses and into the next year. The commercialization efforts for Fanapt in bipolar I disorder are anticipated to contribute significantly to this growth.
PONVORY Revenue Growth: PONVORY revenue is expected to grow, with new patient prescriptions reaching record highs since the commercial launch. The sales force for PONVORY is being expanded to approximately 50 representatives by Q3 2025.
HETLIOZ Revenue Variability: HETLIOZ revenue may experience variability or decline due to generic competition and changes in inventory stocking at specialty pharmacy customers. This could potentially offset growth in other products.
2025 Revenue Guidance: Total revenue from Fanapt, HETLIOZ, and PONVORY is projected to be between $210 million and $250 million, representing a growth of 6% to 26% compared to 2024.
Year-End 2025 Cash Guidance: Year-end 2025 cash is expected to be between $280 million and $320 million, reflecting investments in R&D and commercial strategies.
Bysanti FDA Approval and Market Entry: The NDA for Bysanti for bipolar I disorder and schizophrenia has a PDUFA target action date of February 21, 2026. If approved, exclusivity could extend into the 2040s, and it is expected to contribute to the company's psychiatry portfolio.
Tradipitant FDA Approval: The NDA for tradipitant for motion sickness has a PDUFA target action date of December 30, 2025.
Fanapt Long-Acting Injectable (LAI) Development: The Phase III program for the long-acting injectable formulation of Fanapt for schizophrenia relapse prevention is ongoing, with plans to begin enrolling patients for a hypertension study soon.
Imsidolimab FDA Submission: The BLA for imsidolimab for generalized pustular psoriasis is expected to be submitted to the FDA in 2025.
PONVORY Expansion into New Indications: Studies for PONVORY in psoriasis and ulcerative colitis are planned, with the ulcerative colitis study expected to begin by early 2026.
VQW-765 Phase III Program: The Phase III program for VQW-765, targeting acute performance anxiety, is underway, with patient enrollment expected to begin soon.
VCA-894A Development: The Phase I clinical study for VCA-894A, targeting Charcot-Marie-Tooth disease, is ongoing, with Orphan Drug Designation granted for this indication.
The selected topic was not discussed during the call.
The earnings call reflects mixed signals: while Fanapt and PONVORY show growth, HETLIOZ faces revenue variability. The increased net loss and operating expenses raise concerns, but optimistic guidance and potential FDA approvals for new drugs provide a positive outlook. The Q&A session highlights optimism but lacks specific guidance, tempering expectations. Overall, the sentiment is neutral, with positive and negative elements balancing each other.
The earnings report shows mixed results: strong growth in Fanapt sales but declines in PONVORY and HETLIOZ, coupled with a significant net loss increase due to higher expenses. The Q&A revealed uncertainties about PONVORY's revenue dispute and unclear management responses. Despite some positive guidance on Bysanti and potential future products, the overall sentiment is negative due to financial losses and market uncertainties, likely leading to a stock price decline in the next two weeks.
The earnings call reveals several negative factors: a significant net loss, increased operating expenses, and potential supply chain challenges. The Medicare redesign negatively impacts revenue, and management's unclear responses in the Q&A raise concerns about strategic direction. Although there are some positive developments like Fanapt's growth and new drug applications, they are overshadowed by financial instability and lack of shareholder return plans. These factors suggest a likely negative stock price movement over the next two weeks.
The earnings call presents mixed results: Fanapt sales increased, but Hetlioz faced a decline due to competition. The company revised its revenue guidance upwards, which is positive, but operating expenses and net loss increased. The Q&A revealed some uncertainties, like the sales force's sufficiency and delays in product filings. Overall, the market may react neutrally, balancing positive guidance and product developments with increased losses and expenses.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
